Tunakan Dalgic Ceyda, Camyar Asuman, Mete Gokmen Nihal, Kilincer Bozgul Sukriye Miray, Arun Mehmet Zuhuri, Karaman Zehra Tuba, Ertuna Elif
Department of Internal Medicine, Division of Allergy and Immunology, Faculty of Medicine, Ege University, Bornova, Izmir, Turkey.
Department of Internal Medicine, Faculty of Medicine, Ege University, Bornova, Izmir, Turkey.
J Asthma Allergy. 2023 Jul 21;16:743-753. doi: 10.2147/JAA.S419722. eCollection 2023.
Repeated exposure to platinum compounds increases the risk of immunoglobulin E-mediated immediate hypersensitivity reactions (HSR). To date, many different desensitization protocols with varying success rates have been reported. The presented study is aimed at disseminating the real-world experience of an interdisciplinary healthcare team focusing on platin desensitization.
This is a cross-sectional, retrospective study of 7 female patients with carboplatin- or oxaliplatin-induced HSRs. After a discussion with the oncologist and the patient, desensitization protocols were performed by a team consisting of an allergy and immunology specialist, a clinical pharmacist, and a nurse. Clinical data were extracted from the patients' medical records, and HSRs were reviewed and classified by an allergist according to severity and type.
Twenty-five desensitization protocols were carried out for patients with carboplatin- or oxaliplatin-induced HSRs (N=4 and N=3, respectively; age range: 54-66). Two of the patients did not experience any HSR during a total of 8 desensitization cycles. The other patients had grade 1-3 HSRs on 15 cycles, which were successfully managed by oxygen and/or pharmacological interventions and infusions were resumed at a lower rate after stabilization of the patient. Compared to baseline, serum tryptase levels were elevated during HSRs (4.77±0.21 vs 9.50±1.71, P=0.028).
All the patients were able to finish the treatment protocol and receive full chemotherapeutic doses. Interdisciplinary teams may facilitate the preparation and administration of platinum-based chemotherapeutics and increase the success rates of desensitization protocols for platin-based chemotherapy, where the concentration and application of drugs differ from standard procedure.
反复接触铂类化合物会增加免疫球蛋白E介导的速发型超敏反应(HSR)的风险。迄今为止,已报道了许多成功率各异的不同脱敏方案。本研究旨在传播一个跨学科医疗团队在铂类脱敏方面的实际经验。
这是一项对7例因卡铂或奥沙利铂引起HSR的女性患者进行的横断面回顾性研究。在与肿瘤学家和患者讨论后,由过敏与免疫学专家、临床药剂师和护士组成的团队实施脱敏方案。从患者病历中提取临床数据,过敏症专科医生根据严重程度和类型对HSR进行审查和分类。
对因卡铂或奥沙利铂引起HSR的患者进行了25次脱敏方案(分别为4例和3例;年龄范围:54 - 66岁)。其中2例患者在总共8次脱敏周期中未发生任何HSR。其他患者在15个周期中出现1 - 3级HSR,通过吸氧和/或药物干预成功处理,患者病情稳定后以较低速率恢复输注。与基线相比,HSR期间血清类胰蛋白酶水平升高(4.77±0.21对9.50±1.71,P = 0.028)。
所有患者均能够完成治疗方案并接受全量化疗剂量。跨学科团队可促进铂类化疗药物的配制和给药,并提高铂类化疗脱敏方案的成功率,其中药物浓度和应用与标准程序不同。